We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
+18.68%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$6.69B
AUM Growth
+$682M
Cap. Flow
-$395M
Cap. Flow %
-5.9%
Top 10 Hldgs %
54.02%
Holding
678
New
246
Increased
85
Reduced
72
Closed
235

Top Buys

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$85.8M
2
INDV icon
Indivior Pharmaceuticals
INDV
+$59.6M
3
BCAX
Bicara Therapeutics
BCAX
+$45.8M
4
MRUS
Merus
MRUS
+$34.4M
5
VTRS icon
Viatris
VTRS
+$30M

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$102M
2
SGRY icon
Surgery Partners
SGRY
+$86.4M
3
CPRX
Catalyst Pharmaceutical
CPRX
+$53.7M
4
IART icon
Integra LifeSciences
IART
+$42.8M
5
BNTX icon
BioNTech
BNTX
+$38.6M

Sector Composition

Rank Sector Weight
1 Healthcare 87.45%
2 Industrials 0.73%
3 Technology 0.55%
4 Financials 0.45%
5 Consumer Discretionary 0.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BRBR icon
226
BellRing Brands
BRBR
$1.53B
$682K 0.01%
11,235
+418
+4% +$23.2K
EW icon
227
Edwards Lifesciences
EW
$49.1B
$682K 0.01%
+10,332
New +$751K
CYTK icon
228
Cytokinetics
CYTK
$10.7B
$680K 0.01%
12,884
+8,518
+195% +$475K
SPR
229
DELISTED
Spirit AeroSystems
SPR
$680K 0.01%
20,923
+10,340
+98% +$354K
BIIB icon
230
Biogen
BIIB
$30.8B
$679K 0.01%
3,504
+2,573
+276% +$538K
PARA
231
DELISTED
Paramount Global Class B
PARA
$664K 0.01%
+62,516
New +$680K
TRMB icon
232
Trimble
TRMB
$13.6B
$664K 0.01%
+10,689
New +$597K
CG icon
233
Carlyle Group
CG
$16.3B
$660K 0.01%
+15,332
New +$643K
PRCT icon
234
Procept Biorobotics
PRCT
$1.03B
$656K 0.01%
8,190
-236
-3% -$16.8K
BMRN icon
235
BioMarin Pharmaceuticals
BMRN
$11.9B
$651K 0.01%
9,255
-577
-6% -$48.2K
NAMSW icon
236
NewAmsterdam Pharma Warrant
NAMSW
$75.3M
$650K 0.01%
92,787
– –
SAIC icon
237
Saic
SAIC
$4.98B
$648K 0.01%
4,650
-4,261
-48% -$538K
ELAN icon
238
Elanco Animal Health
ELAN
$12.8B
$634K 0.01%
+43,127
New +$601K
MA icon
239
Mastercard
MA
$501B
$632K 0.01%
+1,280
New +$595K
EBS icon
240
Emergent Biosolutions
EBS
$376M
$632K 0.01%
+75,642
New +$688K
MS icon
241
Morgan Stanley
MS
$325B
$631K 0.01%
+6,049
New +$609K
EVER icon
242
EverQuote
EVER
$962M
$627K 0.01%
+29,712
New +$679K
HROW icon
243
Harrow
HROW
$1.45B
$623K 0.01%
13,863
-11,584
-46% -$392K
ZYME icon
244
Zymeworks
ZYME
$1.62B
$622K 0.01%
+49,546
New +$540K
HBI
245
DELISTED
Hanesbrands
HBI
$612K 0.01%
+83,238
New +$498K
BL icon
246
BlackLine
BL
$1.92B
$611K 0.01%
11,079
+2,209
+25% +$109K
VTLE
247
DELISTED
Vital Energy
VTLE
$610K 0.01%
+22,667
New +$839K
RIOT icon
248
Riot Platforms
RIOT
$7.34B
$609K 0.01%
82,063
+58,731
+252% +$508K
ZIMV
249
DELISTED
ZimVie
ZIMV
$608K 0.01%
+38,329
New +$688K
MKSI icon
250
MKS Inc
MKSI
$18B
$602K 0.01%
+5,541
New +$658K
8 9
10
11 12

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return
AAF
Andra AP-fonden Goteborg, Sweden $8.39B AUM 21.19% 1-Year Est. Return

Deerfield Management's Q3 2024 Portfolio in Review

As of Q3 2024, Deerfield Management held 678 positions worth $6.69B, up 11% from $6.01B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Deerfield Management withdrew a net $395M in Q3 2024, closing 235 positions and reducing 72 holdings. Its most notable exit was Gilead Sciences, an estimated $102M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, up from 83% a quarter earlier, followed by Industrials and Technology.

Against the trend, Deerfield Management opened a new position in Indivior Pharmaceuticals worth $49.7M.

  • Deerfield Management's largest Q3 2024 buy was Indivior Pharmaceuticals: 5,092,642 shares worth $49.7M.
  • Deerfield Management added most to Neurocrine Biosciences in Q3 2024, an estimated $85.8M increase.
  • Deerfield Management's biggest Q3 2024 reduction was Surgery Partners, cutting an estimated $86.4M.
  • Deerfield Management fully exited Gilead Sciences in Q3 2024, selling an estimated $102M.
  • Deerfield Management's ten largest holdings make up 54% of its $6.69B portfolio in Q3 2024.
  • Deerfield Management opened 246 new positions and closed 235 in Q3 2024.
  • Deerfield Management's portfolio value rose 11% quarter-over-quarter to $6.69B.

Based on Deerfield Management's 13F filing for Q3 2024, filed 14 Nov 2024.